Report LibraryAll Reports
Triple-Negative Breast Cancer (TNBC) KOL Interview - US, Midwest #2
September 14, 2023
A US-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for TNBC. Key pipeline assets highlighted include Enhertu, datopotamab deruxtecan, and Cosela.
This interview was conducted on 13 July 2023.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
|Indications Covered:||Triple-Negative Breast Cancer (TNBC)|